We are live on ! Find out more

Teva Pharmaceutical Industries Limited

TEVA

Market cap $45.6B

39.10 USD

-0.09

0.23%

At close Updated Sep 18, 12:31 PM EDT

1 day

-0.23%

5 days

3.82%

1 month

6.89%

3 months

24.21%

6 months

32.05%

Year to date

26.33%

1 year

111.92%

5 years

349.94%

10 years

-22.88%

About: Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 32,842

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.6%

Neutral 42.9%

Negative 3.6%

Schaeffers Research

Most Active Options Report: FPS, TEVA, AFL

These three stocks are seeing some of the most unusual options volume today

Most Active Options Report: FPS, TEVA, AFL

Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) had a busy week that included a major debt refinancing, a milestone shift in how its shares trade on the NYSE and analyst activity.

Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform

Teva Pharmaceutical Industries NYSE: TEVA CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility.

Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform

Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars

Teva Pharmaceutical Industries NYSE: TEVA said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet.

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

PARSIPPANY, N.J. and TEL AVIV, Israel, Sept.

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the “Conditional Redemptions”), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, for general corporate purposes, including the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

Teva Announces Launch of Offering of Senior Notes

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”) intend to offer USD-denominated Senior Notes (the “USD Notes” and, together with the Euro Notes, the “Notes”).

Teva Announces Launch of Offering of Senior Notes

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

Schaeffers Research

Outperforming Pharma Stock Still Has Upside Potential

Teva Pharmaceuticals Industries (NYSE:TEVA) is moving 2.9% lower to trade at $36.41, pulling back from its Aug. 27, nearly nine-year high of $38.36.

Outperforming Pharma Stock Still Has Upside Potential

See News Rankings

Price charts implemented using Lightweight Charts™